Gujarat cancels Health Point Pharma licence, acts against seven firms in codeine trade probe

Gujarat drug regulators cancelled Health Point Pharma’s drug-sale licence and issued or initiated show-cause notices against seven firms over alleged codeine-stock and record irregularities. Sale of 37,762 Rexton-T syrup bottles valued at ₹83.08 lakh was restricted pending investigation.

— Source publishedTue, 8 Sept, 2026, 10:26 IST·First seen Tue, 8 Sept, 2026, 10:35 IST·Source The Hindu BusinessLine

What happened

Balaji Pharma · Gujarat drug regulators cancelled Health Point Pharma’s licence and issued notices to seven firms after finding codeine-medicine stock and

Key facts

  • 1 drug sale licence cancelled
  • 7 firms served or being served show-cause notices
  • 37,762 bottles of Rexton-T Syrup seized/restricted
  • ₹220 MRP per Rexton-T bottle
  • ₹83.08 lakh value of Rexton-T stock
  • 57 bottles of R Tuss TD Syrup restricted
  • ₹9,006 value of R Tuss TD stock

Why this matters

Any distribution, acquisition or partnership diligence involving controlled-drug portfolios should prioritize licence status, stock-record integrity and exposure to ongoing regulatory investigations.

What to watch

  • Formal FIRs, arrests or narcotics-law charges connected to codeine diversion
  • Additional licence cancellations, product seizures or statewide inspection directives
  • Identification of manufacturers, transporters, pharmacies or interstate buyers in the transaction trail
  • Court stays or successful appeals that restore Health Point Pharma's licence or release inventory
  • Evidence that restricted stock was legitimately documented versus unaccounted or diverted
  • Manufacturer notices on supply suspension, distributor termination or revised controlled-drug policies
  • Gujarat drug-control authorities are likely to complete physical stock reconciliation, invoice tracing and buyer verification for the restricted 37,762 Rexton-T bottles.
  • Impacted distributors will seek hearings, submit compliance records and may challenge licence cancellation or suspension orders administratively or in court.
  • Manufacturers supplying codeine-containing syrups may tighten distributor due diligence, dispatch controls, batch tracking and order limits in Gujarat.
  • Retail pharmacies and hospitals may substitute non-codeine cough products if authorized inventory movement remains constrained.
  • Investigators may share findings with police, narcotics and interstate drug regulators if evidence suggests diversion beyond record-keeping violations.